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Novelty and Impact: The investigation is the first to evaluate whether adding serum 
concentrations of sex steroid hormones, metabolic markers, growth factors, 
adipokines, and cytokines improves discrimination of an endometrial cancer risk 
prediction model. Using data from the European Prospective Investigation into 
Cancer and Nutrition (EPIC) cohort, we observed a 2 percentage point improvement 
in discrimination in models including all evaluated hormones and accounting for over-
fitting.
Abstract 
Endometrial cancer risk prediction models including lifestyle, anthropometric, and 
reproductive factors have limited discrimination. Adding biomarker data to these 
models may improve predictive capacity; to our knowledge, this has not been 
investigated for endometrial cancer. Using a nested case-control study within the 
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we 
investigated the improvement in discrimination gained by adding serum biomarker 
concentrations to risk estimates derived from an existing risk prediction model based 
on epidemiologic factors. Serum concentrations of sex steroid hormones, metabolic 
markers, growth factors, adipokines, and cytokines were evaluated in a step-wise 
backward selection process; biomarkers were retained at p<0.157 indicating 
improvement in the Akaike information criterion (AIC). Improvement in discrimination 
was assessed using the C-statistic for all biomarkers alone, and change in C-statistic 
from addition of biomarkers to preexisting absolute risk estimates. We used internal 
validation with bootstrapping (1000-fold) to adjust for over-fitting. Adiponectin, 
estrone, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, and 
triglycerides were selected into the model. After accounting for over-fitting, 
discrimination was improved by 2.0 percentage points when all evaluated biomarkers 
were included and 1.7 percentage points in the model including the selected 
biomarkers. Models including etiologic markers on independent pathways and 
genetic markers may further improve discrimination.  
 
  
Introduction 
Endometrial cancer (EC) risk prediction models identify women who would most likely 
benefit from targeted screening or prevention. Incidence of EC is relatively low, 
estimated at 13.6 cases per year per 100,000 women in Europe.1 Therefore, risk 
prediction models designed to identify “high” vs. lower risk populations of women for 
targeted intervention or screening programs need high specificity to avoid invasive 
follow-up on false positives, while ensuring a high proportion of true high risk women 
are identified.  
Risk models based on questionnaire data alone provide moderate predictive 
capacity for endometrial cancer.2, 3 We recently reported discrimination capacity of 
77% (C statistic) in a model fit in the European Prospective Investigation into Cancer 
and Nutrition (EPIC) cohort;3 this model included body mass index (BMI), 
menopausal status, ages at menarche, first full-term pregnancy and menopause, oral 
contraceptive (OC) use and duration, parity, duration of  hormone therapy (HT), and 
smoking status. Pfeiffer et al. developed an endometrial cancer risk prediction model 
in U.S.-based cohorts, reporting an area under the curve (AUC) of 0.68 for a model 
including a somewhat smaller set of variables than those selected into the model in 
the EPIC cohort (BMI, menopausal status, age at menopause, BMI, OC use, parity, 
HT use and smoking).2 These models provide important insights for future population 
based approaches to predict endometrial cancer risk prediction, although additional 
predictors are needed to improve discrimination. To our knowledge, the extent to 
which circulating biomarkers improve endometrial cancer risk prediction has not been 
addressed. 
A factor analysis within an EPIC nested case-control study identified three 
hormonal and metabolic axes associated with endometrial cancer risk: (i) steroid 
hormones; (ii) insulin resistance/metabolic syndrome; and (iii) inflammation.4 
Biomarkers along these axes have been independently associated with disease risk 
in previous analyses.5-14 We investigate here whether the addition of biomarkers to a 
risk score based on epidemiological questionnaire data improves predictive capacity 
for endometrial cancer.  
Methods 
The EPIC cohort has been described in detail previously.15, 16 Briefly, more than 
500,000 study participants (367,903 women) were recruited from 10 European 
countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, 
Spain, Sweden, and the United Kingdom) between 1992 and 2002. In addition to 
questionnaire-based data and anthropometric measures, serum samples were 
collected at baseline using a standardized protocol; samples and have been in long-
term storage at ≤-150oC, with the exception of Sweden, where samples are stored at 
-70 oC. 
Cohort Follow-up 
Incident cancer cases were identified via record linkage with regional cancer 
registries (Denmark, Sweden, Italy, the Netherlands, Norway, Spain, and the United 
Kingdom), health insurance records, cancer and pathology registries, and active 
follow-up of study subjects (France, Germany, Greece, and Naples, Italy). Data on 
vital status were obtained from mortality registries, in combination with data collected 
by active follow-up. End of follow-up corresponds to latest dates of complete follow-
up for both cancer incidence and vital status (June 1999 - December 2003) at the 
time when the nested case-control analyses were performed. 
 
Case and Control Selection 
Case and control selection has been described in detail previously.5-10 Women with 
known menopausal status, not using exogenous hormones at blood draw (e.g., OC, 
HT), and with no reported hysterectomy or history of cancer (except non-melanoma 
skin cancer) were eligible for this study. Cases were restricted to incident epithelial 
endometrial cancers diagnosed during follow-up; non-epithelial cases were excluded.  
Up to two control subjects were matched to each case, using incidence density 
sampling. Matching factors were: study recruitment center, menopausal status 
(premenopausal, postmenopausal, perimenopausal), age at enrolment (±6 months), 
time of day of blood collection (±1 hour), fasting status (<3 hours; 3–6 hours, >6 
hours) and for premenopausal women, phase of menstrual cycle (follicular, 
periovulatory, luteal). This analysis included 247 cases and 469 matched controls. 
Biomarker measurements 
The biomarkers investigated here include C-reactive protein (CRP), interleukin 6 
(IL6), IL1 receptor antagonist (IL1Ra), tumor necrosis factor-alpha (TNFα), TNF 
receptor 1 (TNFR1), TNFR2, testosterone, dehydroepiandrosterone-sulfate 
(DHEAS), estrone, estradiol, sex hormone binding globulin (SHBG), 
androstenedione, c-peptide, insulin-like growth factor binding protein 1 (IGFBP1), 
IGFBP2, high density lipoprotein (HDL) cholesterol, triglycerides, total cholesterol, 
glucose, and adiponectin. Measurement of the biomarkers has been described in 
detail.4-10 In brief, blood samples from cases and matched controls were analyzed 
within the same analytical batch and laboratory technicians were blinded to the case-
control status of the study subjects. The majority of the assays were performed at the 
International Agency for Research into Cancer (Lyon, France) using commercially 
available immunoassays. Interleukin-1 receptor antagonist and soluble tumor 
necrosis factor (TNF) receptors were measured at the German Cancer Research 
Center (DKFZ; Heidelberg, Germany). Blood lipids were measured at the Hôpital 
Edouard Herriot (Lyon, France) using an enzymatic colorimetric test. Serum estradiol 
concentrations were measured only in postmenopausal women because of the 
variation in estradiol levels during the menstrual cycle among premenopausal 
women. Glucose was not measured in samples from women recruited at the Oxford, 
United Kingdom, study center because samples were kept at room temperature for 
>24 hours before processing, and glucose concentrations are not stable with delayed 
processing.  
Statistical analyses 
All biomarker measurements were log2-transformed. A considerable fraction of IL1Ra 
and TNFα measurements were below the detection limit (LOD) (52% and 18% of 
values below LOD). Indicator variables for IL1Ra and TNFα below LOD were 
included as interaction terms, given the high proportion of values below LOD. 
Sporadic missing analyte values for the remaining biomarkers, for reasons such as 
insufficient volume or technical failure, varied between 0% for C-peptide and IGFBP1 
to 5% for estrone. Missing values for the remaining biomarkers were imputed using 
the center- and menopausal status-specific mean biomarker value. Estrone was 
measured in both pre- and postmenopausal women. Given within-person variability in 
estrone across the menstrual cycle in premenopausal women, we used menstrual 
cycle phase-specific residuals from a local linear regression model. We included an 
interaction term with an indicator variable for post-menopausal status for both estrone 
and estradiol (measured only in postmenopausal women). Biomarker values were 
adjusted for center, age, menopausal status and fasting status (matching factors) and 
regression residuals were used for all further analyses. Absolute risk estimates for all 
subjects were calculated according to the previously defined EC risk model based on 
the full EPIC cohort3 including the following exposures: BMI (kg/m2), menopausal 
status, age at menarche and at menopause, OC use (overall and by BMI categories) 
and duration of use, parity, age at first full-term pregnancy, duration of HT and 
smoking status (by menopausal status). Relative risk estimates of the biomarkers 
were derived with conditional logistic regression, which was calibrated towards the 
absolute risk estimates as an offset-variable. In a step-wise backwards selection 
process biomarkers with a p-value below 0.157, indicating improvement in the Akaike 
information criterion (AIC; i.e., balancing model fit with number of included 
parameters),17 were retained in the model. 
Improvement in risk estimation was assessed with C-statistic (equivalent to the area 
under the receiver operating curve (AUROC)) for all biomarkers alone, and change in 
C from addition of biomarkers to preexisting absolute risk estimates. In addition we 
assessed the integrated discrimination improvement (IDI) and net reclassification 
improvement (NRI; continuous).18  
Internal validation with bootstrapping (1000-fold) was applied to adjust the 
performance outcomes for over-fitting from model development and estimation.17 The 
median “optimism” estimate for the C-statistics, IDI, and NRI was subtracted from the 
observed estimates; optimism was calculated on the full study population. 
Results 
Cases and controls were median age 57 years at recruitment, and the majority of 
study participants were parous, never users of OCs and never smokers, and 
postmenopausal at recruitment (Table 1). Cases had higher BMI at recruitment than 
controls (27.4 vs. 25.7 kg/m2). The 5-year risk of endometrial cancer was estimated 
to be between 0.01% and 3%. Distributions of the investigated biomarkers are 
provided in Supplemental Table 1. 
Among the evaluated biomarkers, only estrone and IL1Ra were statistically 
significantly positively associated with endometrial cancer risk (estrone, ORlog2: 1.54 
(95% CI: 1.16-2.04); IL1Ra among women with values >LOD, ORlog2: 1.26 (1.06-
1.51)) in a multivariate model including EC-risk estimates as offset (i.e., adjusted for 
the variables in the risk prediction model; Table 2). Adiponectin, estrone, IL1Ra, 
TNFα, and triglycerides were selected into the final model using the threshold 
p<0.157.  
The C-statistic of the EC risk prediction model was 62.7% in this sample. After 
accounting for optimism (i.e., over-fitting), the discrimination of a model including 
biomarkers alone was 62.3% (Table 3). The EC risk model was improved by 2.0 
percentage points in the model considering all evaluated biomarkers (C-statistic, EC 
risk model: 62.7%, optimism adjusted, all biomarkers: 64.7%) and by 1.7 percentage 
points in the model including the selected biomarkers (C-statistic: 64.4%). The EC 
risk models had somewhat higher discrimination in models restricted to 
postmenopausal women (C- statistic, EC risk model alone: 65.5%; optimism adjusted 
C- statistic, including all biomarkers: 66.4%; including selected biomarkers: 65.8%). 
The difference between risk estimates for cases and controls increased by an 
average of 0.1% (IDI). The NRI indicates that the model including the selected 
hormones provided a more accurate risk prediction score for 19.0% of cases and 
controls.  
 
 
 Discussion 
Inclusion of biomarkers in an endometrial cancer risk prediction model resulted in 
modest improvements in discrimination. The biomarkers included in this study were 
assessed to investigate biological pathways in the development of EC. The selected 
markers represent intermediates on etiologic pathways (e.g., between adiposity and 
EC risk), but don’t necessarily contribute independent information to other, 
questionnaire based markers related to the same pathways, such as BMI to the 
metabolic syndrome, or reproductive history and hormone-use and the balance of 
sex steroid hormones. This questionnaire information is included in the predefined 
risk score. Thus, after including extensive questionnaire information into the risk 
model, these biomarkers contribute only enough additional, independent information 
to slightly improve prediction. The full predictive potential of the biomarkers alone 
(62.3%) was similar to the discriminative capacity of the comprehensive 
epidemiological risk score (62.7%).  
The aim of this investigation was to investigate the extent to which biomarkers 
improved discrimination of an existing risk prediction model. The performance of the 
endometrial cancer risk model presented here (nested case-control study) is lower 
than the model previously reported (cohort study3) due to the matched case-control 
study design. Endometrial cancer risk is strongly impacted by both age and 
menopausal status, and cases and controls in the present study were matched on 
these factors. Further, duration of menopausal hormone therapy use was an 
important predictor in our questionnaire-based risk prediction model, and women 
using exogenous hormones at blood draw were excluded from the nested case-
control study. 
Our study has several limitations. First, our analysis of model performance is based 
on the case-control data alone, among women not using exogenous hormones at the 
time of the study. We cannot evaluate the extent to which the improvement conferred 
by the selected markers would be observed among exogenous hormone users. The 
study design may limit the accurate interpretation of the discriminative capacity of 
biomarkers due to case and control matching.19, 20 However, inclusion of the 
endometrial cancer risk estimate as a regression offset should provide appropriate 
adjustment to account for the nested case-control study design, as proposed by 
Pepe et al.19 Moreover all biomarkers were adjusted for age, center and menopausal 
status, and therefore potential confounding of our results from these important 
predictors and matching variables has been avoided. Another limitation is the large 
proportion of the measurements on IL1Ra (52%) and TNFa (18%) below the assay 
limit of detection. The effect of missing values was evaluated using three different 
methods: 1) inclusion of an additional categorical marker indicating values below 
detection limit, 2) replacement of values below detection limit with the detection limit, 
and 3) exclusion of these markers from the common model. Overall, the risk 
estimates were similar from the three approaches, thus we present only results from 
the first approach. Finally, we used bootstrapping for internal validation in this study 
as it has been suggested as the most efficient technique to address optimism due to 
overfitting.17 We did not have data available for external validation. 
We observed only modest improvement in discrimination after incorporating 
biomarker concentrations in endometrial cancer risk prediction models. Future 
models should include hormones and etiologic markers on independent pathways 
and confirmed genetic markers to further improve discrimination.  
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